A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

Author： Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.122, Iss.2, 2010-07, pp. : 429-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

By Aogi Kenjiro   Saeki Toshiaki   Nakamura Seigo   Kashiwaba Masahiro   Sato Nobuaki   Masuda Norikazu   Rai Yoshiaki   Ohno Shinji   Kuroi Katsumasa   Nishimura Reiki   Miyakoda Keiko   Akiyama Futoshi   Kurosumi Masafumi   Ikeda Tadashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 598-606

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

By Kümmel Sherko   Thomas Anke   Paepke Stefan   Schwarz Marion   Heinrich Georg   Wetzel Andrea   Elling Dirk   Kohls Andreas   Lichtenegger Werner   Blohmer Jens-Uwe  

Acta Oncologica, Vol. 44, Iss. 3, 2005-05 ,pp. : 248-254

Informa Healthcare

Access to resources Recommend Favorite

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

By Ramaswamy Bhuvaneswari   Povoski Steven   Rhoades Chris   Allen Joan   Hauger Marsha   Young Donn   Burak William   Farrar William   Yee Lisa   Kendra Kari   Somasundaram Sivagurunathan   Orlowski Robert   Shapiro Charles  

Breast Cancer Research and Treatment, Vol. 93, Iss. 1, 2005-09 ,pp. : 67-74

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite